Last reviewed · How we verify

DaxibotulinumtoxinA for injection — Competitive Intelligence Brief

DaxibotulinumtoxinA for injection (DaxibotulinumtoxinA for injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Aesthetics, Neurology.

phase 3 Botulinum toxin SNARE complex (acetylcholine release machinery) Aesthetics, Neurology Biologic Live · refreshed every 30 min

Target snapshot

DaxibotulinumtoxinA for injection (DaxibotulinumtoxinA for injection) — Revance Therapeutics, Inc.. DaxibotulinumtoxinA is a botulinum toxin that blocks acetylcholine release at the neuromuscular junction, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DaxibotulinumtoxinA for injection TARGET DaxibotulinumtoxinA for injection Revance Therapeutics, Inc. phase 3 Botulinum toxin SNARE complex (acetylcholine release machinery)
incabotulinumtoxinA incabotulinumtoxinA Multiple Sclerosis Center of Northeastern New York marketed Botulinum toxin type A SNARE complex (synaptobrevin/VAMP)
MYOBLOC MYOBLOC Supernus Pharmaceuticals, Inc. marketed Botulinum toxin type B VAMP/synaptobrevin (SNARE protein)
Onabotulinum Toxin A Onabotulinum Toxin A Walter Reed National Military Medical Center marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)
Abobotulinum toxin A Abobotulinum toxin A Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)
Chemodenervation (4 months) Chemodenervation (4 months) University of Wisconsin, Madison marketed Botulinum toxin SNARE complex (synaptobrevin, SNAP-25, syntaxin)
Onabotulinumtoxin A Onabotulinumtoxin A Wake Forest University Health Sciences marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

  1. Galderma R&D · 2 drugs in this class
  2. Hexsel Dermatology Clinic · 2 drugs in this class
  3. Seoul National University Hospital · 2 drugs in this class
  4. University of Utah · 2 drugs in this class
  5. Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
  6. EuBiologics Co.,Ltd · 1 drug in this class
  7. Allergan · 1 drug in this class
  8. GlaxoSmithKline · 1 drug in this class
  9. Beth Israel Deaconess Medical Center · 1 drug in this class
  10. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DaxibotulinumtoxinA for injection — Competitive Intelligence Brief. https://druglandscape.com/ci/daxibotulinumtoxina-for-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: